Total Brain Ltd
ASX:TTB
P/S
Price to Sales
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
Market Cap | P/S | ||||
---|---|---|---|---|---|
AU |
Total Brain Ltd
ASX:TTB
|
267.4k AUD | 0 | ||
US |
C
|
Cigna Group
XMUN:CGN
|
89B EUR | 0.5 | |
US |
Cigna Corp
NYSE:CI
|
95.7B USD | 0.5 | ||
US |
CVS Health Corp
NYSE:CVS
|
71.6B USD | 0.2 | ||
US |
Laboratory Corporation of America Holdings
NYSE:LH
|
17.4B USD | 1.4 | ||
DE |
Fresenius SE & Co KGaA
XETRA:FRE
|
15.5B EUR | 0.6 | ||
US |
Quest Diagnostics Inc
NYSE:DGX
|
15.9B USD | 1.7 | ||
DE |
Fresenius Medical Care AG
XMUN:FME
|
11.8B EUR | 0.6 | ||
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.6B EUR | 0.6 | |
US |
DaVita Inc
NYSE:DVA
|
12.2B USD | 1 | ||
US |
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | 4.4 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.